<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124227</url>
  </required_header>
  <id_info>
    <org_study_id>PDinCHF</org_study_id>
    <secondary_id>2009-017711-15</secondary_id>
    <nct_id>NCT01124227</nct_id>
  </id_info>
  <brief_title>Peritoneal Dialysis in Congestive Heart Failure</brief_title>
  <acronym>PDinCHF</acronym>
  <official_title>Symptomatic Improvement by Peritoneal Dialysis in Patients With End Stage Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martini Hospital Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche BV Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martini Hospital Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: End-stage congestive heart failure is a serious invalidating condition with a poor
      prognosis and increasing incidence. Non-randomized observations showed peritoneal dialysis
      (PD) in these patients to improve clinically from NYHA stadium III-IV to as low as NYHA
      stadium I-II. A randomized trial is needed to test whether PD improves symptoms in this
      condition and to find an optimal scheme.

      Objective: To improve symptomatology in severe chronic failure patients. Study design: Open,
      parallel intervention trial comparing 2 schemes of peritoneal dialysis with icodextrin
      (Extraneal®) with standard medical therapy..

      Study population: Patients with chronic refractory left ventricular congestive heart failure
      (LVEF &lt; 30%, older than 18 years).

      Intervention: Peritoneal dialysis with one (night) or two (night and day) dwells with
      icodextrin (Extraneal®).

      Main study parameters/endpoints: Reduction in NYHA classification of symptomatic Congestive
      Heart Failure at 8 months after start of PD therapy. Burden of congestive heart failure:
      measured by reduction in unfavorable days (noted by patients in diaries and including days of
      hospitalization for CHF-deterioration and death).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in NYHA class I, II, III, or IV as measure of quality of life</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measures</measure>
    <time_frame>8 months</time_frame>
    <description>Reduction in unfavorable days. Short-Form 36. Minnesota Living with Heart failure Questionnaire. 6 minute walk test. (re)hospitalization. Survival. Medication optimalisation. Cardial: LVH. Renal: GFR/ERPF/FF; KIM-1, NGAL, NAG. Volume status: ECV (radioactive and bio-impedance). Neurohumoral and inflammatory parameters.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Icodextrin PD changes / day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1 Icodextrin PD change/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icodextrin</intervention_name>
    <description>2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.</description>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_label>2 Icodextrin PD changes / day</arm_group_label>
    <arm_group_label>1 Icodextrin PD change/day</arm_group_label>
    <other_name>Extraneal</other_name>
    <other_name>RVG 21300</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Refractory Left Ventricular Congestive Heart Failure: LVEF &lt; 30%

          -  Diminished renal function: eGFR &lt; 60 ml/min

          -  Clinically volume overloaded (Dyspnoea (NYHA III-IV), edema, and/or ascites)

          -  Hospitalization for CHF during the last 6 months

          -  Patient is on optimal cardiologic medical therapy, which has been stable for more than
             4 weeks

          -  Suitable for PD

        Exclusion Criteria:

          -  Hypotension (SBP &lt; 100 mmHg / MAP &lt; 70) mmHg

          -  Instable AP or recent (&lt; 6 months) myocardial infarction.

          -  Contraindications for PD (e.g. visual handicap, social)

          -  Liver failure

          -  COPD Gold class IV

          -  Malignancy with life expectancy &lt; 2 years

          -  Non compliance

          -  No informed consent

          -  Poor mental health
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilbert M Janssen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martini Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilbert M Janssen, MD, PhD</last_name>
    <phone>+31-50-5247911</phone>
    <email>w.m.t.janssen@mzh.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Femke Waanders, MD, PhD</last_name>
    <phone>+31-50-5247761</phone>
    <email>f.waanders@mzh.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Martini Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wilbert M Janssen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Femke Waanders, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Posma, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martini Hospital Groningen</investigator_affiliation>
    <investigator_full_name>Wilbert Martien Theodoor Janssen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Symptomatic improvement</keyword>
  <keyword>Renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

